Carl Zeiss Meditec/€AFX
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Carl Zeiss Meditec
Carl Zeiss Meditec AG, publicly traded under the ticker symbol AFX, specializes in the healthcare technology sector. Founded in 2002 as a spin-off from Carl Zeiss AG, it provides comprehensive medical solutions for ophthalmology and microsurgery. Operating globally, the company combines its expertise in optics, electronics, and precision engineering to offer innovative products that enhance patient care and clinical outcomes.
Ticker
€AFX
Sector
Primary listing
XETRA
Employees
5,713
AFX Metrics
BasicAdvanced
€3.8B
24.92
€1.71
1.21
€0.60
1.40%
Price and volume
Market cap
€3.8B
Beta
1.21
52-week high
€71.65
52-week low
€40.52
Average daily volume
25K
Dividend rate
€0.60
Financial strength
Total debt to equity
28.461
Interest coverage (TTM)
5.95%
Profitability
EBITDA (TTM)
226.546
Gross margin (TTM)
52.00%
Net profit margin (TTM)
6.89%
Operating margin (TTM)
8.12%
Effective tax rate (TTM)
23.00%
Revenue per employee (TTM)
€380,000
Management effectiveness
Valuation
Price to earnings (TTM)
24.917
Price to revenue (TTM)
1.716
Price to book
1.8
Price to tangible book (TTM)
9.65
Dividend yield (TTM)
1.40%
Forward dividend yield
1.40%
Growth
Revenue change (TTM)
5.49%
Earnings per share change (TTM)
-24.65%
3-year revenue growth (CAGR)
6.96%
10-year revenue growth (CAGR)
8.28%
3-year earnings per share growth (CAGR)
-14.48%
10-year earnings per share growth (CAGR)
7.24%
What the Analysts think about AFX
Analyst ratings (Buy, Hold, Sell) for Carl Zeiss Meditec stock.
Bulls say / Bears say
In the second quarter of fiscal 2024/25, Carl Zeiss Meditec reported revenues of €560 million, up 19%, and EBITA of €78 million, beating consensus estimates. This performance was driven by a strong recovery in China’s refractive procedures market. (Reuters)
The company has kept its guidance for fiscal 2024/25 unchanged, expecting moderate revenue growth and EBITA to remain stable or slightly improve—demonstrating management's confidence, even with ongoing risks from possible US trade tariffs and currency fluctuations. (Reuters)
Goldman Sachs upgraded Carl Zeiss Meditec to a “buy” rating and set a price target of €74, citing stabilization in the China refractive business and modest upward adjustments to EBITA forecasts for FY25-27. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
AFX Financial Performance
Revenues and expenses
AFX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Carl Zeiss Meditec stock?
Carl Zeiss Meditec (AFX) has a market cap of €3.8B as of September 12, 2025.
What is the P/E ratio for Carl Zeiss Meditec stock?
The price to earnings (P/E) ratio for Carl Zeiss Meditec (AFX) stock is 24.92 as of September 12, 2025.
Does Carl Zeiss Meditec stock pay dividends?
Yes, the Carl Zeiss Meditec (AFX) stock pays dividends to shareholders. As of September 12, 2025, the dividend rate is €0.6 and the yield is 1.4%. Carl Zeiss Meditec has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Carl Zeiss Meditec dividend payment date?
The next Carl Zeiss Meditec (AFX) dividend payment date is unconfirmed.
What is the beta indicator for Carl Zeiss Meditec?
Carl Zeiss Meditec (AFX) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.